1-phenyl-3,3-dimethyltriazene and Wet Macular Degeneration

1-phenyl-3,3-dimethyltriazene has been researched along with Wet Macular Degeneration in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adachi, K; Barzey, V; Fukuda, A; Yanagi, Y	1

Other Studies

1 other study(ies) available for 1-phenyl-3,3-dimethyltriazene and Wet Macular Degeneration

Article	Year
Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. Journal of medical economics, 2017, Volume: 20, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Cost-Benefit Analysis; Drug Costs; Female; Health Expenditures; Humans; Intravitreal Injections; Japan; Male; Photosensitizing Agents; Quality-Adjusted Life Years; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triazenes; Wet Macular Degeneration	2017

Article

Year

Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.

Journal of medical economics, 2017, Volume: 20, Issue:2

Topics: Aged; Angiogenesis Inhibitors; Cost-Benefit Analysis; Drug Costs; Female; Health Expenditures; Humans; Intravitreal Injections; Japan; Male; Photosensitizing Agents; Quality-Adjusted Life Years; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triazenes; Wet Macular Degeneration

2017